newsfilter
← Latest News
Business Wire·

GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn

Sierra Oncology's differentiated momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia Momelotinib complements GSK's existing expertise in haematology, with Sierra Oncology anticipating US